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Abstract
Background: Substance use in pregnancy is associated with severe maternal and fetal morbidities and substantial
economic costs. However, few studies have evaluated the cost-effectiveness of substance use treatment programs
in pregnant women. The purpose of this study was to evaluate the economic impact of a behavioral intervention
that integrated motivational enhancement therapy with cognitive behavioral therapy (MET-CBT) for treatment of
substance use in pregnancy, in comparison with brief advice.
Methods: We conducted an economic evaluation alongside a clinical trial by collecting data on resource utilization
and performing a cost minimization analysis as MET-CBT and brief advice had similar effects on clinical outcomes
(e.g., alcohol and drug use and birth outcomes). Costs were estimated from the health care system’s perspective
and included intervention costs, hospital facility costs, physician fees, and costs of psychotropic medications from
the date of intake assessment until 3-month postpartum. We compared effects of MET-CBT on costs with those of
brief advice using Wilcoxon rank sum tests.
Results: Although the integrated MET-CBT therapy had higher intervention cost than brief advice (median = $1297/
participant versus $303/participant, p < 0.01), costs of care during the prenatal period, delivery, and postpartum
period, as well as for psychotropic medications, were comparable between the two groups (all p values ≥ 0.55).
There was no statistically significant difference in overall cost of care (median total cost = $26,993/participant for
MET-CBT versus $27,831/participant for brief advice, p = 0.90).
Conclusions: The MET-CBT therapy and brief advice resulted in similar clinical outcomes and overall medical costs.
Further research incorporating non-medical costs, targeting women with more severe substance use disorders, and
evaluating the impact of MET-CBT on participants’ quality of life will provide additional insights.
Trial registration: ClinicalTrials.gov NCT00227903. Registered 27 September 2005.
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Background
Use of illicit drugs, alcohol and tobacco during preg-
nancy is associated with severe maternal and fetal mor-
bidities, such as placental abruption, birth defects,
preterm birth, drug withdrawal syndromes and longer-
term developmental problems [1–4]. Illicit drug use by
pregnant women also increases their risk for human im-
munodeficiency virus (HIV) infection and subsequent
risk for vertical transmission to infants [1, 5].
The rate of substance use in pregnancy is high and it
is associated with substantial economic costs. National
survey data showed that in the U.S., 5.9, 8.5 and 15.9%
of pregnant women 15–44 years of age reported current
use of illicit drugs, alcohol and cigarettes, respectively, in
2011–2012 [6]. Treatment for opioids-exposed newborns
cost $70.6-$112.6 million in the U.S. in 2009 [7], and the
average lifetime cost for a newborn with fetal alcohol
syndrome was estimated to be $2.0 million in 2002 [8].
Although pregnant substance users have unique med-
ical, psychological and social care needs, few studies
have evaluated substance use treatment programs tai-
lored to pregnant women and the limited number of
studies available have targeted particular substances,
such as nicotine or alcohol alone [9, 10], rather than
women who use a variety of substances which is com-
mon in pregnant substance users [11]. Moreover, litera-
ture on the economic impact of these interventions is
sparse [12], despite growing concerns about health care
spending. Their clinical effectiveness needs to be care-
fully weighed against cost consequences in order to de-
liver high-value care.
In this study, we conducted an economic evaluation of
an innovative intervention integrating motivational en-
hancement therapy with cognitive behavioral therapy
(MET-CBT), in comparison with brief advice, designed
for reducing substance use and HIV risk behaviors in
pregnant women who use an array of substances. The
findings will inform future allocation of resources for ad-
dressing substance use in pregnancy.
Methods
Intervention and participants
This study was an economic evaluation alongside a ran-
domized controlled trial (RCT), i.e., Therapeutic Sub-
stance Abuse Treatment in Pregnancy-1 (PRIDE-P) trial.
Details about the design, intervention, methods, and
main clinical outcomes of the PRIDE-P trial are reported
elsewhere [13]. Briefly, an MET-CBT intervention was
designed to reduce substance use in pregnancy, decrease
risky sexual behaviors, and improve birth outcomes.
Pregnant women who used substances (alcohol,
marijuana, cocaine, or stimulants but not solo use of
opiates or nicotine) during the 28 days prior to screen-
ing or scored at least a “3” on the modified TWEAK
(Tolerance, Worried, Eye-openers, Amnesia, K[C] Cut
Down) screening test were eligible if they were 16 years
of age or older and less than 28 weeks of gestation at the
time of screening [13–15]. Patients whose primary sub-
stance was opioid or nicotine were excluded because
methadone maintenance programs are the established
treatment for patients with opioid use disorders and the
study sites already had standard nicotine treatment pro-
tocols at the time of this study. Participants were ran-
domly assigned to receive either the MET-CBT
intervention or brief advice.
Women assigned to the MET-CBT group received
one-on-one therapy from a trained nurse therapist at
prenatal visits with optional booster visits after delivery
(average number of sessions completed = 5.2). Each ses-
sion lasted for about 30 min. Topics covered included:
motivational enhancement, functional analysis (non-drug
activities and triggers/patterns), safe sexual behavior,
communication skills, relapse prevention, and problem-
solving skills.
For participants assigned to receive brief advice, their
routine obstetric providers provided brief guidance
about the risks of substance use, importance of abstin-
ence, and benefit of seeking drug and alcohol treatment
outside of the prenatal setting (average number of ses-
sions = 7.2). This discussion occurred within the routine
prenatal/postpartum visits and each lasted for about
1 min.
A total of 168 study participants were recruited from
two hospital-based reproductive health clinics between
June 2006 and July 2010 [13]. Only one study site was
able to provide complete cost data; hence, our analysis
focused on the subset of participants who received pre-
natal care and delivered at this site in order to perform a
comprehensive economic evaluation. This resulted in an
analytical sample size of 112 participants, of which 60
were randomized to MET-CBT and 52 received brief
advice.
Clinical effectiveness
Results on clinical effectiveness of the integrated MET-
CBT therapy, relative to brief advice, in the PRIDE-P
trial are detailed elsewhere [13]. Briefly, participants
were assessed at baseline, delivery, and 3-month postpar-
tum. The primary outcome measure for clinical effective-
ness was the percentage of days that a participant used
alcohol or any drug during the prior 28 days [13, 16].
Secondary outcomes included whether the participant
was abstinent from substances (alcohol and drugs) ac-
cording to self-report, urine toxicology test, or combined
self-report and urine toxicology test, respectively;
whether she was abstinent from alcohol according to
breathalyzer tests; the Addiction Severity Index (ASI)
[17] composite scores for alcohol and drug use;
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participants’ sexual behaviors; and birth outcomes. Be-
cause there were no statistically significant treatment
effects on primary or secondary clinical outcomes [13],
the economic evaluation constituted a cost minimization
analysis wherein, given similar effectiveness, we assessed
which intervention was associated with lower costs.
Cost
Economic evaluation was conducted from the health
care system’s perspective. Measurement of costs in-
cluded intervention costs, hospital facility costs, phys-
ician fees, and costs of psychotropic medications.
Timeframe of the cost analysis began from the date of
intake assessment until 3-month postpartum. Because
this timeframe was less than 1 year, no discounting was
needed. Intervention costs were determined using a
micro-costing technique taking into consideration the
quantity and unit price of all inputs used for the design
and implementation of the MET-CBT intervention and
brief advice [18]. Research-induced costs during the
intervention (e.g., staff time spent on data entry) were
excluded. Data on hospital facility costs were obtained
from the institutional accounting database and therefore
reflected actual medical resources consumed by partici-
pants and their newborns at each encounter (rather than
charges or reimbursements). Physician costs were esti-
mated based on actual payments received using data
from a billing database for professional fees at the study
site. Collectively, these hospital facility costs and phys-
ician costs encompassed all medical care services re-
ceived by participants and their newborns at the study
site from intake assessment until 3-month postpartum,
including pregnancy-related as well as other medical ser-
vices. To help elucidate the economic impact of the
study interventions by phase of care, we categorized
costs according to the time period when they occurred
(i.e., prenatal period, labor and delivery, and postpartum
period) and stratified by care for the mother versus the
newborn. In addition, we reviewed medical records and
obtained information on name, dose, frequency and dur-
ation of psychotropic medications used by participants
during the study period. Average wholesale prices from
Red Book Drug Topics [19] were used to estimate the
cost of medications. Costs occurring in different years
were inflation adjusted to 2012 U.S. dollars using the
medical care component of consumer price index [20].
Statistical analysis
We used non-parametric Wilcoxon rank sum test for all
comparisons of costs between MET-CBT and brief ad-
vice due to skewed distribution of cost data. Four partic-
ipants had otherwise complete data but lacked
information on physician cost for their labor and deliv-
ery hospitalization. For them, we applied a diagnosis-
related group (DRG)-specific, average physician cost to
hospital facility cost ratio (whenever feasible) or inter-
vention group-specific average physician cost for labor
and delivery based on the rest of the sample. Participants
with other types of missing data (e.g., lacked data on
physician costs entirely) were excluded from the primary
analysis. In all statistical tests, p values less than 0.05
were considered statistically significant.
In a sensitivity analysis, we included participants with
missing costs by imputing their values using sample
average costs from their corresponding intervention
group (MET-CBT versus brief advice), setting (physician
cost, hospital facility cost, versus medication cost), and
time period (prenatal, labor and delivery, versus postpar-
tum) or based on DRG-specific, average physician cost
to hospital facility cost ratio (when feasible). For missing
data on costs of psychotropic medications, we imputed
the value using intervention group-specific average
medication cost. In addition, three participants had twin
pregnancies. As these pregnancies were substantially
more expensive which might unduly influence compari-
son of costs due to the relatively small sample size, we
conducted another sensitivity analysis focusing on par-
ticipants with singleton births only.
Results
Participant characteristics
Participants’ mean age was 25.1 years (standard devi-
ation = 6.1) (Table 1). Over half (53.2%) were black, and
25.9% were Hispanic. Thirty-five percent had less than
high school education, and most participants (94.6%)
had Medicaid coverage. Marijuana was the most fre-
quently reported primary substance, followed by alcohol
and cocaine. Over half of the participants (51.8%) re-
ported ever regularly using more than one substance,
and 32.1% of the participants were determined as alco-
hol/drug abuse or dependent according to the Mini-
International Neuropsychiatric Interview (MINI) [21].
Average gestation age at the time of enrollment was
20.1 weeks.
Costs
Intervention cost was significantly higher for MET-
CBT than for brief advice (median = $1297/participant
versus $303/participant, p < 0.01) because of its
higher set-up costs and longer session duration
(Table 2) [18]. This difference, however, was oversha-
dowed by the substantial medical costs that occurred
during the period of pregnancy, delivery, and postpar-
tum. The median per participant cost during pre-
natal, delivery and postpartum period was $6339,
$15,493, and $1272, respectively, for participants re-
ceiving MET-CBT, compared with $6591, $15,175,
and $1254, respectively, for participants receiving
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brief advice (all p values ≥ 0.55). Costs of psycho-
tropic medications were also similar between the two
groups (median = $124 versus $136, p = 0.70). Overall,
there was no statistically significant difference in total
cost of care for participants between the two groups
(median = $26,993/participant in MET-CBT versus
$27,831/participant in brief advice, p = 0.90).
Distributions of costs were right skewed as a small
number of participants incurred high costs. For example,
20 mothers (17.9%) stayed in hospital for longer than
4 days; and of the 114 newborns with known length of
stay (including 3 pairs of twins), 24 (21.1%) were admit-
ted for more than 10 days. As a result, mean overall cost
was much higher than the median (mean = $43,294/par-
ticipant and $47,693/participant for MET-CBT and brief
advice, respectively). Maternal and newborn hospital stay
for delivery accounted for the largest share of the overall
cost (71.1% for the MET-CBT group and 73.6% for the
brief advice group), followed by care received during the
prenatal period (19.4 and 16.9% for MET-CBT and brief
advice, respectively) (Fig. 1).
Similar results were found in sensitivity analyses when
only singleton births were included and when partici-
pants with missing data were included with imputed
values. Median per participant cost was $26,817 for
MET-CBT versus $27,537 for brief advice (p = 0.82) and
$26,314 for MET-CBT versus $27,537 for brief advice (p =
0.97), respectively (Table 3).
Discussion
Drawing on data from pregnant women who used
substances and participated in the PRIDE-P trial, we
conducted an economic evaluation of a novel behav-
ioral intervention aimed to reduce substance use and
HIV risk behaviors and improve birth outcomes.
There was no statistically significant difference in
main clinical outcomes between the MET-CBT and
brief advice groups [13]. Our cost minimization ana-
lysis showed that the overall cost of care was similar
between the two groups, and was primarily influenced
by labor and delivery cost.
One strength of this study is our comprehensive meas-
urement of costs associated with the care of pregnant
women, including intervention costs, costs during the
prenatal period, and maternal and newborn costs up to
3 months postpartum, as well as both hospital facility
costs and physician costs. In contrast, prior economic
evaluations of substance use programs for pregnant
women were often limited to drug treatment costs or se-
lected care components (e.g., neonatal intensive care
unit costs) [22–25]. Few have assessed the impact of
intervention on overall maternal and newborn costs.
In addition, by conducting an economic evaluation in
the context of a randomized trial, we were able to
rigorously assess the financial consequences of the
intervention as potential impact of unobserved con-
founding factors was minimized. In contrast, previous
studies evaluating the economic impact of substance
use treatment programs in pregnancy were largely
based on non-randomized designs limiting their abil-
ity to draw causal inferences [22–27].







Age (in years) 25.1 ± 6.1 25.4 ± 5.8 24.8 ± 6.4
Race
White 36 (32.4%) 19 (32.2%) 17 (32.7%)
Black 59 (53.2%) 31 (52.5%) 28 (53.8%)
Other 16 (14.4%) 9 (15.3%) 7 (13.5%)
Hispanic ethnicity
Yes 29 (25.9%) 17 (28.3%) 12 (23.1%)
No 83 (74.1%) 43 (71.7%) 40 (76.9%)
Education (in years)
< 12 39 (35.1%) 20 (33.3%) 19 (37.3%)
12 42 (37.8%) 20 (33.3%) 22 (43.1%)
13–15 25 (22.5%) 16 (26.7%) 9 (17.7%)
≥ 16 5 (4.5%) 4 (6.7%) 1 (2.0%)
Type of insurance/payer
Medicaid 106 (94.6%) 54 (90.0%) 52 (100.0%)
Other 6 (5.4%) 6 (10.0%) 0 (0.0%)
Parity
0 42 (37.5%) 22 (36.7%) 20 (38.5%)
1 34 (30.4%) 21 (35.0%) 13 (25.0%)
≥ 2 36 (32.1%) 17 (28.3%) 19 (36.5%)
Gestation age at time of
enrollment, weeks
20.1 ± 7.2 20.3 ± 7.3 20.0 ± 7.2
Primary drug
Alcohol 36 (32.1%) 18 (30.0%) 18 (34.6%)
Cocaine 23 (20.5%) 12 (20.0%) 11 (21.2%)
Marijuana 44 (39.3%) 24 (40.0%) 20 (38.5%)
Other 9 (8.0%) 6 (10.0%) 3 (5.8%)
Ever regularly used more
than one substance
Yes 57 (51.8%) 33 (56.9%) 24 (46.2%)
No 53 (48.2%) 25 (43.1%) 28 (53.8%)
MINI drug/alcohol
abuse/dependence
Yes 36 (32.1%) 23 (38.3%) 13 (25.0%)
No 76 (67.9%) 37 (61.7%) 39 (75.0%)
MET-CBT motivational enhancement therapy with cognitive behavioral therapy,
MINI Mini-International Neuropsychiatric Interview. Statistics were reported as
n (%) or mean ± standard deviation. Percentages may not add up to 100% due
to rounding
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Our study suggests that health care for substance
using women and their newborns is costly. This finding
is consistent with other studies. For example, Whiteman
et al. [28] reported that hospital facility cost alone aver-
aged $5616 for pregnancy-related hospitalizations for
women with opioid use in the U.S. during 1998–2009.
Fingar et al. [29] also showed that in 2012, hospital facil-
ity cost for newborn stays related to substance use aver-
aged $19,684, compared to $4500 for other newborns.
One recent study by Goler et al [30] assessed costs of
care for women receiving Early Start, an integrated pre-
natal intervention providing one-to-one counseling to
pregnant women at risk for substance use [31]. Average
cost of maternal and newborn care from prenatal until
1 year postpartum totaled $20,644 per participant, com-
pared to $27,812 per non-participant substance user.
Cost savings from medical care more than offset the
program implementation cost [30]. Our cost estimates
may be somewhat higher than these studies because a
large proportion of participants in our study were
Table 2 Comparison of per participant costs between brief advice and integrated motivational enhancement and cognitive
behavioral therapy
Cost Category Brief Advice (n = 58) MET-CBT (n = 48) P value
Median (Interquartile range) Median (Interquartile range)
Intervention $303 ($264-$329) $1297 ($1178-$1491) <0.01
Prenatal period $6591 ($4819-$9909) $6339 ($3436-$9977) 0.55
Labor and delivery
Mother $9399 ($7664-$11,745) $9516 ($7101-$12,113) 0.91
Baby $3611 ($2410-$18,816) $3708 ($2219-$24,704) 0.88
Mother + Baby $15,175 ($11,194-$32,926) $15,493 ($10,352-$33,507) 0.94
3-month postpartum period
Mother $385 ($225-$763) $657 ($258-$1196) 0.12
Baby $757 ($235-$1278) $820 ($394-$1275) 0.63
Mother + Baby $1254 ($775-$2434) $1272 ($818-$2782) 0.65
Medication $136 ($0-$194) $124 ($0-$187) 0.70
Total $27,831 ($19,694-$48,273) $26,993 ($21,240-$45,289) 0.90
six participants were excluded from primary analysis due to missing cost data. MET-CBT motivational enhancement therapy with cognitive behavioral therapy
Fig. 1 Distribution of cost categories. MET-CBT =motivational enhancement therapy with cognitive behavioral therapy. Percentages may not add
up to 100% due to rounding
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polysubstance users and might be less healthy than pa-
tients in other studies. For example, 16.5% of our sample
participants delivered preterm versus 7.7–15.4% in the
various groups of substance users in Goler et al. [30]. In
addition, we included costs associated with all medical
services delivered during the study period, including
those that were not directly pregnancy-related. This is to
fully capture the impact of our study intervention which
might improve participants’ health behavior and hence
have broader impact on resource utilization.
Our data from the PRIDE-P trial showed that com-
pared with brief advice, MET-CBT did not reduce over-
all medical costs up to 3-month postpartum. Several
factors may explain this lack of a significant difference.
First, pregnancy itself may substantially affect women’s
health behavior, confounding and overshadowing the ef-
fect of MET-CBT. Second, many participants in our
sample had relatively low substance use at baseline. In-
formation provided in the brief advice intervention, in-
cluding informing women of the adverse health impact
of substance use (on both the mother and the fetus) and
where additional treatment could be received, may be
sufficient for these patients, making it difficult to ob-
serve the additional benefit of MET-CBT. Third, we de-
signed MET-CBT as a one-on-one therapy to best match
existing prenatal care at the study sites. This format is
more costly than group therapy.
Further research assessing MET-CBT in patients with
more severe substance use disorders or examining similar
interventions in a group therapy setting will be informative.
More research on the impact of similar psychotherapy on
women’s overall quality of life will also be informative as
participants may experience improved well-being and so-
cial support despite lack of significant improvement in sub-
stance use. In addition, the PRIDE-P trial suggested a trend
toward a reduction in preterm birth by MET-CBT as com-
pared to brief advice (preterm birth rate = 10% versus 20%,
p = 0.08) although the study was not powered to assess this
outcome [13]. Future studies with larger sample sizes test-
ing the potential benefit of MET-CBT intervention in re-
ducing preterm birth and the associated cost implications
will provide additional insights.
This study has several limitations. First, our data were
based on an RCT at a single study site. The findings may
not be generalizable to all pregnant women who use sub-
stance or receive care elsewhere. Second, we estimated
medical costs occurring within the study institution. Partic-
ipants could have received care elsewhere which was not
captured in our cost estimates. Third, physician cost data
were unattainable at one of the study sites, precluding us
from including all PRIDE-P trial participants in this ana-
lysis and reducing our statistical power for detecting differ-
ences between groups. Comparison between the two study
sites also suggested that participants in our analysis were
more likely to report marijuana as their primary substance
(as opposed to alcohol at the other site) and a higher pro-
portion of them were drug/alcohol abuse or dependent.
However, data on hospital facility costs were available at
both sites. Comparison of hospital facility costs between
MET-CBT and brief advice groups at the other study site
suggested no statistically significant difference either, cor-
roborating our main findings. Finally, we were unable to
perform the economic evaluation from a societal perspec-
tive as data on participants’ transportation costs and prod-
uctivity loss were only collected for intervention visits but
not available for other medical encounters. Likewise, we
did not have data on costs associated with legal services or
child custody that often occur with substance use and can
be costly. Future studies incorporating non-medical costs
and longer follow-up times would be informative.
Conclusions
Substance use in pregnancy remains an important issue
in obstetric care. Identifying cost-effective treatment op-
tions not only benefits the mother and her family, but
also society. Our analysis of data from the PRIDE-P trial
found that, compared with brief advice, a behavioral
intervention integrating MET and CBT had similar effect
on substance use and birth outcomes [13], and did not
reduce overall medical costs up to 3-month postpartum.
Continued effort to compare MET-CBT in patients with
more severe substance use disorders or in different for-
mats (e.g., group therapy) and to evaluate its impact on
participants’ quality of life will further inform the poten-
tial role of behavioral interventions in managing sub-
stance use in pregnancy. Future research should also
assess the potential benefit of brief advice itself in pro-
moting abstinence in substance users.
Table 3 Sensitivity analyses of per participant costs between brief advice and integrated motivational enhancement and cognitive
behavioral therapy
Brief Advice MET-CBT P value
Analysis Median (Interquartile Range) Median (Interquartile Range)
Base case analysis $27,831 ($19,694-$48,273) $26,993 ($21,240-$45,289) 0.90
Limiting to singleton births $27,537 ($19,354-$45,131) $26,817 ($21,070-$44,172) 0.82
Including participants with missing data (via imputation) $27,537 ($18,891-$47,519) $26,314 ($20,538-$43,914) 0.97
MET-CBT motivational enhancement therapy with cognitive behavioral therapy
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